About Us
Nanophysics & Beyond
Curadigm
The Management
Our Commitments
Healthcare Professionals
Scientific Publications
Patients
Patient Engagement
Shareholders
Corporate Presentation
Financial Calendar
Regulated Information
Annual General Meetings
Shareholder Corner
Press Releases
Nanotalks
NBTXR3 Development
Head & Neck Cancer
R&D Day
Congresses
& Events
Our Expert Videos
From Curie to Nano
Contact & Newsletter
Medical Device Vigilance – Pharmacovigilance
Medical Information
Join Us
Nous vous informons que ce site est conforme à la législation française actuelle sur les dispositifs médicaux.
Continuer
Rester sur la page
Scientific Clinical | FDA approved Investigational New Drug for NBTXR3 in a new clinical study in prostate cancer
Financial | Nanobiotix Revenue Q3 2015
13 November 2015
Financial | Nanobiotix completes a EUR 21 million private placement
11 March 2016
Scientific Clinical | FDA approved Investigational New Drug for NBTXR3 in a new clinical study in prostate cancer
Published by
Julie Ficheux
on
4 January 2016
No translations available for this page
